Ó³»­´«Ã½

Patrick Ellinor is an institute member and director of the Cardiovascular Disease Initiative and the Precision Cardiology Laboratory at the Ó³»­´«Ã½. He is the interim chief of cardiology and co-director of the Corrigan-Minehan Heart Center at Massachusetts General Hospital (MGH) and a professor of medicine at Harvard Medical School. His clinical focus is on the treatment of cardiac arrhythmias.

Ellinor’s lab uses genetics to elucidate the molecular basis underlying abnormalities of the heart rhythm and heart function. Much of his recent work has focused on atrial fibrillation, the most common arrhythmia. To identify novel pathways for atrial fibrillation, he has used a broad range of techniques, including population genetics, electrophysiology, and animal models of arrhythmias.

Ellinor currently helps to lead the AFGen Consortium, an international group of investigators studying the genetics of atrial fibrillation. Over the past 15 years, he has been continuously funded by the National Institutes of Health, he has received an Established Investigator Award from the American Heart Association (AHA), and he is a principal investigator on a Transatlantic Network of Excellence Program sponsored by the Fondation Leducq. Ellinor also co-leads a unique academic industrial partnership between the Ó³»­´«Ã½ and Bayer focused on identifying novel therapeutic targets for cardiovascular disease. He is a member of the AHA, the Heart Rhythm Society, and the American Society of Clinical Investigation.

Ellinor received his B.S. in biology from University of Cincinnati and attended medical and graduate school at Stanford University, followed by medical internship and residency at Brigham and Women's Hospital. He then came to MGH for his fellowship training in cardiology and cardiac electrophysiology. He joined the faculty of the Cardiac Arrhythmia Service and the Cardiovascular Research Center at MGH in 2003.